As Merck’s Keytruda Gains Momentum, Investors Look To The Future
This article was originally published in The Pink Sheet Daily
Executive Summary
Keytruda, already the first anti-PD-1 drug to market for melanoma, received FDA breakthrough therapy designation for an indication in lung cancer. The drug’s long-term potential – and upcoming data on a two-drug hepatitis C combo – helped to offset a decline in Merck’s third quarter sales.
You may also be interested in...
Emerging Markets Earnings: China A Star For Merck Key Product Sales
Merck looks for growth in key products across emerging markets to keep full-year earnings in check even as it revises down its forecast for revenues.
Safety Profile Of Merck’s Anti-PD-1 Keytruda Shines In FDA Labeling
Priced at $12,500/month, Keytruda will be ready to ship within one week of FDA approval for relapsed melanoma after failure of Yervoy and a BRAF inhibitor. Approval could spur interest in off-label use of PD-1 inhibitor as a first-line treatment.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”